-45%

est. 2Y upside i

Healthcare

Rank

#3486

Sector

Biotechnology

Est. Liquidity

~0Y

Data Quality

Data: High

The job seeker would receive equity in Merck & Co.

Last updated: March 10, 2026

Bull (30%)+40%

Sotatercept (WINREVAIR) significantly exceeds sales expectations, reaching multi-billion dollar peak sales by 2028 and expanding into additional indications, while Reblozyl's global royalties from Bristol Myers Squibb grow substantially. This strong performance, coupled with other pipeline successes, drives Merck's market capitalization to over $450B, providing a robust return for equity holders.

Base (50%)+15%

Sotatercept achieves its projected multi-billion dollar sales in PAH, becoming a key growth driver for Merck. Reblozyl continues to generate steady royalties, but further indication expansions are limited. Merck maintains its market position, growing revenue at a moderate pace, leading to a market capitalization of approximately $370B within two years.

Bear (20%)-25%

Sotatercept faces unexpected safety concerns, intense competition, or slower-than-anticipated market adoption, failing to meet sales forecasts. Reblozyl's expansion efforts falter, and Merck struggles to effectively diversify its portfolio ahead of Keytruda's patent expiration. This leads to a decline in investor confidence and Merck's market capitalization falling to around $240B.

Est. time to liquidity~0.0 years

Preference Stack Risk

low

Funding Intensity

4%

As a public company, Merck's equity does not have liquidation preferences that would disadvantage common stock holders in the same way as private company preferred shares.

Dilution Risk

low

Merck, as a large public company, has a vast number of outstanding shares, so employee equity grants typically result in minimal percentage dilution.

Secondary Liquidity

active

Merck stock is publicly traded on the NYSE, offering immediate and active liquidity for vested equity.

View all 2 open roles at Acceleron →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Acceleron's data — designed to show you've done your homework.

  • 1

    “With Sotatercept now approved and showing strong efficacy, how is Merck strategizing its global commercialization and market access to maximize its potential in the competitive PAH landscape?”

  • 2

    “Given the mixed results for Reblozyl's expansion into new indications, what is Merck's long-term strategy for this asset, particularly in collaboration with Bristol Myers Squibb?”

  • 3

    “As a large public company, how does Merck ensure that the innovative spirit and scientific expertise of acquired entities like Acceleron are maintained and integrated effectively into its broader R&D efforts, especially concerning employee equity and career growth within a large organization?”

Community

Valuation Sentiment

Our model estimates -45% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.